Related Experiment Video

Updated: May 22, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Single agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant

Signe R Michaelsen1, Camilla L Christensen, Maxwell Sehested

  • 1Department of Radiation Biology, The Finsen Center, National University Hospital, Copenhagen, Denmark.

The Journal of Gene Medicine
|May 12, 2012
PubMed
Abstract

Insights

Targeted suicide gene therapy using the INSM1 promoter effectively kills chemoresistant small cell lung cancer (SCLC) cells. Combination therapies, including standard chemotherapy, show superior efficacy in treating SCLC tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapy

Background:

  • Small cell lung cancer (SCLC) often develops chemoresistance.
  • Insulinoma-associated 1 (INSM1) promoter drives targeted suicide gene (SG) therapy in SCLC.
  • The efficacy of INSM1-driven SG therapy in chemoresistant SCLC is not fully understood.

Purpose of the Study:

  • To evaluate the effectiveness of INSM1 promoter-driven SG therapy in chemoresistant SCLC.
  • To investigate the impact of chemoresistance on INSM1 promoter activity.
  • To explore combination strategies for enhanced SCLC treatment.

Main Methods:

  • Characterized chemoresistant SCLC cell lines for drug resistance and INSM1 promoter activity.
  • Tested SG therapy using Yeast cytosine deaminase-uracil phosphoribosyl transferase (YCD-YUPRT)/5-fluorocytosine (5-FC) and Escherichia coli nitroreductase (NTR)/SN27686.
  • Assessed cytotoxicity in both chemosensitive and chemoresistant SCLC models.

Main Results:

  • Chemoresistant SCLC cells showed heterogeneous resistance profiles but maintained or increased INSM1 promoter activity.
  • INSM1-driven SG therapy induced significant cytotoxicity in both sensitive and resistant SCLC cells.
  • Combination therapies (SG+chemotherapy or dual SG) were superior to single-agent therapy in chemoresistant SCLC.

Conclusions:

  • INSM1 promoter-driven SG therapy is a viable treatment for chemoresistant SCLC.
  • Combination SG therapy or SG therapy combined with chemotherapy offers the highest efficacy.
  • This approach holds promise for improving outcomes in SCLC patients with acquired resistance.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.